A postural drop (measured after standing for 13 minutes) of 20 mmHg systolic or 10 mmHg diastolic is clinically significant
Risk of Aborted Procedures and the Need to Repeat As a result of the increased risk of RGC with GLP-1 RAs and the subsequent increase in the risk of limited visibility and peri-procedural aspiration, the use of these agents can result in aborted procedures and the need to repeat for better visualization
The SUSTAIN 7 trial compared once-weekly semaglutide (0.5 mg or 1 mg) with once-weekly dulaglutide (0.75 mg or 1.5 mg) in patients with type 2 diabetes over 40 weeks
or 31.9 kg - 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory) - 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients - 65.3% of 12mg patients dropped below the obesity BMI threshold - 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%) - significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP - no cardiac or liver signals Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time
Choose your injection site: Abdomen (most common) Thigh Upper arm Insert the needle at a 90 angle, press the button, and hold